At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KROS Keros Therapeutics, Inc.
Post-Market Trading 09-19 18:37:22 EDT
57.32
+1.61
+2.89%
盘后56.93
-0.39-0.68%
16:36 EDT
High58.28
Low56.30
Vol393.95K
Open57.21
D1 Closing55.71
Amplitude3.55%
Mkt Cap2.15B
Tradable Cap1.86B
Total Shares37.52M
T/O22.49M
T/O Rate1.22%
Tradable Shares32.39M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.